Literature DB >> 20370855

First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi.

Nanja A C van Geel1, Ilse G Mollet, Sofie De Schepper, Esther P M Tjin, Karim Vermaelen, Rachael A Clark, Thomas S Kupper, Rosalie M Luiten, Jo Lambert.   

Abstract

Segmental vitiligo is often ascribed to the neurogenic theory of melanocyte destruction, although data about the initial etiopathological events are scarce. Clinical, histopathological and T-cell phenotypic analyses were performed during the early onset of a segmental vitiligo lesion in a patient with associated halo nevi. Histopathological analysis revealed a lymphocytic infiltrate, mainly composed of CD8+ T-cells and some CD4(+) T-cells around the dermo-epidermal junction. Flow cytometry analysis of resident T-cells revealed a clear enrichment of pro-inflammatory IFN-gamma producing CD8+ T-cells in lesional skin compared to the non-lesional skin. Using human leukocyte antigen-peptide tetramers (MART-1, tyrosinase, gp100), increased numbers of T cells, recognizing melanocyte antigens were found in segmental vitiligo lesional skin, as compared with the non-lesional skin and the blood. Our findings indicate that a CD8+ melanocyte specific T cell-mediated immune response, as observed in generalized vitiligo, also plays a role in segmental vitiligo with associated halo nevi.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20370855     DOI: 10.1111/j.1755-148X.2010.00703.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  13 in total

Review 1.  The genetics of vitiligo.

Authors:  Richard A Spritz
Journal:  J Invest Dermatol       Date:  2011-11-17       Impact factor: 8.551

2.  Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference.

Authors:  K Ezzedine; H W Lim; T Suzuki; I Katayama; I Hamzavi; C C E Lan; B K Goh; T Anbar; C Silva de Castro; A Y Lee; D Parsad; N van Geel; I C Le Poole; N Oiso; L Benzekri; R Spritz; Y Gauthier; S K Hann; M Picardo; A Taieb
Journal:  Pigment Cell Melanoma Res       Date:  2012-05       Impact factor: 4.693

3.  GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1.

Authors:  Matthew P Rausch; K Taraszka Hastings
Journal:  J Invest Dermatol       Date:  2011-08-11       Impact factor: 8.551

Review 4.  Vitiligo--part 1.

Authors:  Roberto Gomes Tarlé; Liliane Machado do Nascimento; Marcelo Távora Mira; Caio Cesar Silva de Castro
Journal:  An Bras Dermatol       Date:  2014 May-Jun       Impact factor: 1.896

5.  Prevalence and Clinical Characteristics of Itch in Vitiligo and Its Clinical Significance.

Authors:  Vasanop Vachiramon; Woranit Onprasert; Sarawin Harnchoowong; Kumutnart Chanprapaph
Journal:  Biomed Res Int       Date:  2017-07-30       Impact factor: 3.411

Review 6.  Clinical and Molecular Aspects of Vitiligo Treatments.

Authors:  Anuradha Bishnoi; Davinder Parsad
Journal:  Int J Mol Sci       Date:  2018-05-18       Impact factor: 5.923

Review 7.  Immunological Parameters Associated With Vitiligo Treatments: A Literature Review Based on Clinical Studies.

Authors:  Ana Cláudia Guimarães Abreu; Gabriela Guy Duarte; Juliana Yasmin Pains Miranda; Daniel Gontijo Ramos; Camila Gontijo Ramos; Mariana Gontijo Ramos
Journal:  Autoimmune Dis       Date:  2015-09-17

8.  Coexistence of Parry-Romberg syndrome with homolateral segmental vitiligo.

Authors:  Marta Janowska; Katarzyna Podolec; Sylwia Lipko-Godlewska; Anna Wojas-Pelc
Journal:  Postepy Dermatol Alergol       Date:  2013-12-18       Impact factor: 1.837

9.  Segmental and generalized vitiligo: both forms demonstrate inflammatory histopathological features and clinical mosaicism.

Authors:  Venkat Ratnam Attili; Sasi Kiran Attili
Journal:  Indian J Dermatol       Date:  2013-11       Impact factor: 1.494

Review 10.  Concise review of recent studies in vitiligo.

Authors:  Mohamed Allam; Hassan Riad
Journal:  Qatar Med J       Date:  2013-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.